Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Marketing-Related Intangible Assets by Quarter
Marketing-Related Intangible Assets — Accumulated Amortization ($M) ($M)
Amgen Marketing-Related Intangible Assets: $1,202M in Q2 2026, unchanged from a year earlier.
Latest, Q2 2026
1,202
Period ended Jun 30, 2026
Change on a year earlier
0.0%
1,202 in Q2 2025
History
37 quarters
Since Q4 2015
Sources
34
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Goodwill and Other Intangible Assets Note (XBRL).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Marketing-Related Intangible Assets — Accumulated Amortization ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,202 | 0.0% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,202 | 0.0% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,203 | +0.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,202 | +1.2% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,202 | +2.8% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,202 | +4.7% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,202 | -4.9% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,188 | -4.4% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,169 | -2.2% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,148 | -3.4% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,264 | +8.3% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,243 | +8.5% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,195 | +6.2% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,188 | +5.2% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 1,167 | +4.9% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 1,146 | +4.3% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 1,125 | +4.3% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,129 | +6.6% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,112 | +6.8% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 1,099 | +7.9% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,079 | +7.6% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 1,059 | +8.2% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 1,041 | +7.9% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2020 | Sep 30, 2020 | 1,019 | +4.8% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,003 | +4.6% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2020 | Mar 31, 2020 | 979 | +3.4% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 965 | -5.3% | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2019 | Sep 30, 2019 | 972 | -1.0% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 959 | -0.8% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 947 | -0.1% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,019 | +10.8% | Form 10-Q (filed 2019-10-30) ↗ |
| Q3 2018 | Sep 30, 2018 | 982 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 967 | – | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2018 | Mar 31, 2018 | 948 | – | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2017 | Dec 31, 2017 | 920 | +16.0% | Form 10-K (filed 2019-02-13) ↗ |
| Q4 2016 | Dec 31, 2016 | 793 | +22.0% | Form 10-K (filed 2018-02-13) ↗ |
| Q4 2015 | Dec 31, 2015 | 650 | – | Form 10-K (filed 2017-02-14) ↗ |
Cite this data
StockData. (2026). Amgen Marketing-Related Intangible Assets ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fl-mktg-accum
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.